Christine Ahlström

Title: Christine Ahlström: Innovator in Endothelin Related Treatments

Introduction

Christine Ahlström is a notable inventor based in Mölndal, Sweden. She has made significant contributions to the field of medicine, particularly in the treatment of endothelin related diseases. With a total of 2 patents to her name, Ahlström's work is recognized for its innovative approach to healthcare.

Latest Patents

Ahlström's latest patents include a groundbreaking combination of zibotentan and dapagliflozin for the treatment of endothelin related diseases. This patent focuses on the use of the endothelin receptor antagonist (ERA) zibotentan in conjunction with the sodium-dependent glucose cotransporter 2 (SGLT-2) inhibitor dapagliflozin. This combination aims to provide effective treatment options for patients suffering from specific endothelin related conditions.

Career Highlights

Christine Ahlström is currently employed at AstraZeneca AB, a leading global biopharmaceutical company. Her work at AstraZeneca has allowed her to collaborate with other experts in the field, enhancing her research and development efforts.

Collaborations

One of her notable collaborators is Peter Greasley, with whom she has worked closely on various projects related to her patents. Their partnership exemplifies the importance of teamwork in advancing medical innovations.

Conclusion

Christine Ahlström's contributions to the field of medicine through her patents and collaborations highlight her role as a key innovator in the treatment of endothelin related diseases. Her work continues to pave the way for advancements in healthcare solutions.